Clinical Trial

18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated December 16, 2024 (before its estimated October 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.
Trial Details
NCT Number NCT06734572
Lead Sponsor First Affiliated Hospital of Fujian Medical University
Conditions Malignant Neoplasm
Enrollment 5 participants
Start Date 2024-06-25
Primary Completion 2025-10-01 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-12-16